Healthcare [ 13/13 ] | Biotechnology [ 106/161 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jan 8, 24 | 0 Increased by +100% | 0.02 Decreased by -100% |
| Nov 8, 23 | 0.01 Increased by +112.5% | -0.01 Increased by +200% |
| Aug 9, 23 | -0.03 Increased by +57.14% | -0.02 Decreased by -50% |
| May 10, 23 | -0.03 Increased by +70% | -0.04 Increased by +25% |
| Mar 23, 23 | -0.06 Increased by +33.33% | -0.06 |
| Nov 9, 22 | -0.08 Increased by +38.46% | -0.08 |
| Aug 10, 22 | -0.07 Increased by +50% | -0.08 Increased by +12.5% |
| May 11, 22 | -0.1 Increased by +37.5% | -0.08 Decreased by -25% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 67.27 M Increased by +63.72% | 2.57 M Increased by +112.52% | Increased by +3.81% Increased by +107.65% |
| Jun 30, 23 | 60.12 M Increased by +77.33% | -6.37 M Increased by +65.29% | Decreased by -10.6% Increased by +80.43% |
| Mar 31, 23 | 56.91 M Increased by +95.56% | -12.76 M Increased by +63.74% | Decreased by -22.43% Increased by +81.46% |
| Dec 31, 22 | 49.98 M Increased by +89.45% | -25.93 M Decreased by -55.75% | Decreased by -51.88% Increased by +17.79% |
| Sep 30, 22 | 41.09 M Increased by +98.69% | -20.48 M Decreased by -15.63% | Decreased by -49.85% Increased by +41.8% |
| Jun 30, 22 | 33.91 M Increased by +90.15% | -18.36 M Increased by +2.91% | Decreased by -54.14% Increased by +48.94% |
| Mar 31, 22 | 29.1 M Increased by +81.34% | -35.2 M Decreased by -91.52% | Decreased by -120.95% Decreased by -5.61% |
| Dec 31, 21 | 26.38 M Increased by +89.04% | -16.65 M Increased by +14.21% | Decreased by -63.11% Increased by +54.62% |
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.